Holdings of Squadron Capital Management LLC
26 declared positions · as of Mar 31, 2026
Original filing · Ten largest lines: 78.3 % of the equity sleeve
Sector breakdown
- Unattributed 100.0 %
Titelia classification, company by company. The unattributed share stays visible.
Currency breakdown
- USD 100.0 %
The quoted currency of each line, as declared.
Country breakdown
- US 88.8 %
- FR 7.5 %
- KY 3.7 %
Shares computed on the equity sleeve.
| Country | Lines | Value | Share |
|---|---|---|---|
| US | 23 | 207.7M $ | 88.80 % |
| FR | 2 | 17.4M $ | 7.46 % |
| KY | 1 | 8.8M $ | 3.74 % |
Positions
| Company | Shares | Value | Weight |
|---|---|---|---|
| Relmada Therapeutics Inc | 8,474,571 | 59M $ | |
| Cogent Biosciences Inc | 787,492 | 30.3M $ | |
| KalVista Pharmaceuticals Inc | 985,100 | 19.8M $ | |
| Kodiak Sciences Inc | 380,000 | 14.5M $ | |
| Abivax SA | 130,000 | 14.5M $ | |
| Edgewise Therapeutics Inc | 350,000 | 11M $ | |
| Nektar Therapeutics | 125,000 | 9M $ | |
| Adlai Nortye Ltd. | 1,265,231 | 8.8M $ | |
| Zentalis Pharmaceuticals Inc | 3,631,000 | 8.5M $ | |
| Maze Therapeutics Inc | 257,500 | 7.7M $ | |
| SCYNEXIS INC | 7,608,695 | 7M $ | |
| Relay Therapeutics Inc | 672,500 | 6.7M $ | |
| C4 Therapeutics Inc | 2,250,000 | 5.9M $ | |
| Inhibikase Therapeutics Inc | 3,500,000 | 5.9M $ | |
| Palisade Bio Inc | 3,000,000 | 5.3M $ | |
| Lipocine Inc | 450,000 | 3.6M $ | |
| Inventiva SACA | 535,000 | 3M $ | |
| ALX Oncology Holdings Inc | 1,460,000 | 2.9M $ | |
| Context Therapeutics Inc | 1,100,000 | 2.9M $ | |
| NextCure Inc | 265,000 | 2.8M $ | |
| PASITHEA THERAPEUTICS CORP | 2,100,000 | 1.6M $ | |
| TRAWS PHARMA INC | 511,714 | 936.4K $ | |
| TherapeuticsMD Inc | 420,421 | 849.3K $ | |
| SPRUCE BIOSCIENCES INC | 12,200 | 797.3K $ | |
| WEREWOLF THERAPEUTICS INC | 563,535 | 469.2K $ | |
| NEUPHORIA THERAPEUTICS INC | 76,728 | 312.3K $ |